Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial

被引：28
|
作者：
Araujo, John C.
Trudel, Geralyn C.
Saad, Fred
Armstrong, Andrew J.
Yu, Evan Y.
Bellmunt, Joaquim
Wilding, George
McCaffrey, John
Serrano, Sergio V.
Matveev, Vsevolod
Efstathiou, Eleni
Oudard, Stephane
Morris, Michael J.
Sizer, Bruce
Goebell, Peter J.
De Bono, Johann Sebastian
Paliwal, Prashni
Durham, Susan
Cheng, Shinta
Logothetis, Christopher
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Seattle Canc Care Alliance, Seattle, WA USA
[3] Univ Hosp Mar, IMIM, Barcelona, Spain
[4] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA
[5] ICORG, Dublin, Ireland
[6] Hosp Canc Barretos, Sao Paulo, Brazil
[7] NN Blokhin Canc Res Ctr, Moscow, Russia
[8] Univ Athens, Dept Clin Therapeut, Athens, Greece
[9] Georges Pompidou European Hosp, Dept Med Oncol, Paris, France
[10] Mem Sloan Kettering Canc Ctr, Genitourinary Oncol Serv, New York, NY 10021 USA
[11] Essex Cty Hosp, Colchester, Essex, England
[12] Univ Erlangen Nurnberg, Dept Urol, D-91054 Erlangen, Germany
[13] Royal Marsden Hosp, Inst Canc Res, Sutton, Surrey, England
[14] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
[15] Bristol Myers Squibb Co, Princeton, NJ USA
[16] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Onol, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 06期
关键词：
D O I：
10.1200/jco.2013.31.6_suppl.lba8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA8
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer
    Madan, Ravi A.
    Karzai, Fatima H.
    Ning, Yang-Min
    Adesunloye, Bamidele A.
    Huang, Xuan
    Harold, Nancy
    Couvillon, Anna
    Chun, Guinevere
    Cordes, Lisa
    Sissung, Tristan
    Beedie, Shaunna L.
    Dawson, Nancy A.
    Theoret, Marc R.
    McLeod, David G.
    Rosner, Inger
    Trepel, Jane B.
    Lee, Min-Jung
    Tomita, Yusuke
    Lee, Sunmin
    Chen, Clara
    Steinberg, Seth M.
    Arlen, Philip M.
    Gulley, James L.
    Figg, William D.
    Dahut, William L.
    BJU INTERNATIONAL, 2016, 118 (04) : 590 - 597
  • [42] Phase Ib trial of docetaxel, prednisone, and pazopanib, in men with metastatic castration resistant prostate cancer (mCRPC).
    George, Daniel J.
    Halabi, Susan
    Healy, Patrick
    Gemberling, Sarah
    Winters, Carolyn
    Mundy, Kelly
    Harrison, Michael Roger
    Szmulewitz, Russell Zelig
    Armstrong, Andrew J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [43] Cabozantinib for metastatic castration-resistant prostate cancer (mCRPC) following docetaxel: Combined analysis of two phase III trials.
    Pond, Gregory Russell
    Sonpavde, Guru
    Fizazi, Karim
    De Bono, Johann S.
    Basch, Ethan M.
    Scher, Howard I.
    Smith, Matthew Raymond
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [44] Impact of Serum γ-Glutamyltransferase on Overall Survival in Men with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel
    Une, Minami
    Takemura, Kosuke
    Inamura, Kentaro
    Fukushima, Hiroshi
    Ito, Masaya
    Kobayashi, Shuichiro
    Yuasa, Takeshi
    Yonese, Junji
    Board, Philip G.
    Koga, Fumitaka
    CANCERS, 2021, 13 (21)
  • [45] Phase II Randomized Study of Figitumumab plus Docetaxel and Docetaxel Alone with Crossover for Metastatic Castration-Resistant Prostate Cancer
    de Bono, Johann S.
    Piulats, Josep M.
    Pandha, Hardev S.
    Petrylak, Daniel P.
    Saad, Fred
    Aparicio, Luis Miguel A.
    Sandhu, Shahneen K.
    Fong, Peter
    Gillessen, Silke
    Hudes, Gary R.
    Wang, Tao
    Scranton, Judith
    Pollak, Michael N.
    CLINICAL CANCER RESEARCH, 2014, 20 (07) : 1925 - 1934
  • [46] The impact of prior therapy with ketoconazole (keto) on clinical outcomes after subsequent docetaxel treatment in metastatic castration-resistant prostate cancer (mCRPC) patients: Results from a randomized phase III trial (CALGB 90401)
    Small, Eric Jay
    Halabi, Susan
    Carducci, Michael Anthony
    Ryan, Charles J.
    George, Daniel J.
    Mahoney, John Francis
    Stadler, Walter Michael
    Morris, Michael J.
    Kantoff, Philip
    Monk, J. P.
    Kelly, William Kevin
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [47] Overall survival (OS) prognostic factors in metastatic castrate-resistant prostate cancer (mCRPC) patients retreated with docetaxel (D)
    Shah, Shilpa Rashmikant
    Albany, Costantine
    Hahn, Noah M.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [48] Results of a phase II study of sunitinib (SU) maintenance after response to docetaxel in metastatic castration-resistant prostate cancer (mCRPC)
    Eigl, Bernhard J.
    Eliasziw, Misha
    North, Scott A.
    Trudeau, Marc G.
    Winquist, Eric
    Chi, Kim N.
    Ruether, Joseph D.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [49] A phase III, randomized, double-blind trial of nivolumab or placebo combined with docetaxel for metastatic castration-resistant prostate cancer (mCRPC; CheckMate 7DX)
    Drake, C. G.
    Saad, F.
    Clark, W. R.
    Ciprotti, M.
    Sharkey, B.
    Subudhi, S. K.
    Fizazi, K.
    ANNALS OF ONCOLOGY, 2020, 31 : S546 - S546
  • [50] Phase III, Randomized, Placebo-Controlled Study of Docetaxel in Combination With Zibotentan in Patients With Metastatic Castration-Resistant Prostate Cancer
    Fizazi, Karim S.
    Higano, Celestia S.
    Nelson, Joel B.
    Gleave, Martin
    Miller, Kurt
    Morris, Thomas
    Nathan, Faith E.
    McIntosh, Stuart
    Pemberton, Kristine
    Moul, Judd W.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (14) : 1740 - +
12345